Time to buy DNA!, page-151

The loan will be fully paid off in July next year from memory. The company will then become a serious cash cow (assuming management don't decide to buy another asset anyway). I think we need some clarity around future dividend levels for the stock to rerate significantly. The problem is I don't think management even have a firm view on this (in terms of say a set payout ratio). If they do they clearly haven't let the analysts know. Baillieu Holst have a dividend forecast for FY18 of $0.04 whilst Canaccord Genuity have got $0.02. If it turns out to be the former it'll be on a yield of over 10% and will surely rerate. If it's the latter, I wouldn't be nearly as excited....